Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

NCT03566576 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

18

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG: Anlotinib
DRUG: Pemetrexed
DRUG: Docetaxel

Sponsor

Fujian Cancer Hospital